Science

At Enanta, we are committed to creating important, novel medicines by pursuing bold ideas, employing rigorous research, and striving for scientific excellence in everything we do. We are fortunate to have some of the best and brightest minds across pharma and biotech working at Enanta. We are passionate about science and dedicated to discovering and developing highly differentiated therapeutics through innovative chemistry to treat diseases in areas of high unmet need. These efforts have resulted in developing drugs for combination regimens that have cured hundreds of thousands of people with chronic hepatitis C virus infection. It’s incredibly rewarding for our scientific expertise to have such an impact on patient lives, and this drives us to do it again in other disease areas.

As part of our drug discovery efforts, we have published several posters, presentations and manuscripts highlighting the depth of our scientific expertise. To review our literature, please see below.

Publications

Filter by Program

RSV: EDP-938
RSV: EDP-323
COVID-19: EDP-235
HBV: EDP-514
NASH: EDP-305
NASH: EDP-297
Other

Filter by Format

Poster
Presentation
Publication
Slides
Date
Source
Title
Program
Format
image for EDP-235, a Potent, Once-Daily Oral Antiviral Treatment for COVID-19
October 20, 2022
Discovery on Target 2022
COVID-19: EDP-235
Presentation
image for EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus
October 1, 2022
12th International RSV Symposium
RSV: EDP-323
Presentation
image for An Improved Toolkit for In Vitro hMPV Characterization
September 30, 2022
12th International RSV Symposium
Other
Poster
image for EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge
February 17, 2022
The New England Journal of Medicine
RSV: EDP-938
Publication
image for EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and Preventative for COVID-19
October 19, 2021
ISIRV WHO Virtual Conference 2021
COVID-19: EDP-235
Poster
image for Mechanism and structural basis of small molecule inhibition of PAPD5 and PAPD7
September 27, 2021
HBV International Meeting
Other
Presentation
image for EDP 938-101 Phase 2a Study: Human Challenge Study
June 14, 2019
Enanta.com
RSV: EDP-938
Slides
image for Discovery and Development of Novel and Potent Non-Fusion Inhibitors of RSV
November 29, 2018
RESPIDart
RSV: EDP-938
Presentation
image for EDP-305 Favorably Regulates Lipoprotein Mechanism In Vitro
October 20, 2017
AASLD 2017
NASH: EDP-305
Poster